Precigen Actobio

Industriepark Zwijnaarde 7C
9052 Zwijnaarde
BE
Precigen Actobio
Foundation date
03/07/2006
Sector
#Biotechnology - TherapeuticsSubsector
- #Therapeutics - Drug delivery
- #Therapeutics - Peptides
- #Therapeutics - Proteins
- #Therapeutics - Antibodies
Therapeutic areas
- #Digestive system
- #Diseases of the blood and blood-forming organs - immune disorders
- #Endocrine - nutritional and metabolic diseases
- #Neoplasms / cancer / oncology
- #Respiratory system
Precigen ActoBio™ is a clinical stage biotechnology company pioneering a new class of therapeutic agents created on the ActoBiotics™ platform. These are targeted, microbe-based, specifically designed agents that express and locally deliver potential disease-modifying therapeutics at disease sites including the intestine, the mouth and the nasopharynx, to treat a range of disorders.
We have a strong R&D pipeline and an extensive portfolio of candidates advancing toward clinical development across a number of potential indications.
Precigen ActoBio™ is a wholly-owned subsidiary of Precigen.
Upcoming events
All events-
0106 '23
KNOWLEDGE FOR GROWTH 2023
Event by: flanders.bio -
0506 '23
BIO International Convention 2023
Event by: Biotechnology Innovation Organisation -
2206 '23
Translational Research in Crops
Event by: VIB
Latest news
More news-
Mithra appoints experienced life sciences executive Christian Homsy* as Chairman
12 hours ago
Read more
-
Oxurion reaches enrollment target in KALAHARI Phase 2, Part B trial of novel PKal inhibitor THR-149 in diabetic macular edema
Friday May 26th 2023
Read more
-
How garbage disposal clogs in cells can lead to Alzheimer’s
Friday May 26th 2023
Read more
Jobs
More jobs-
30/05/23
Remote, Brussels, Abroad
Executive, Chief Financial Officer - European Operations
Permanent, Freelance
General Inception -
-